ID   PGFRB_HUMAN             Reviewed;        1106 AA.
AC   P09619; B5A957; Q8N5L4;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1989, sequence version 1.
DT   10-MAY-2017, entry version 214.
DE   RecName: Full=Platelet-derived growth factor receptor beta;
DE            Short=PDGF-R-beta;
DE            Short=PDGFR-beta;
DE            EC=2.7.10.1;
DE   AltName: Full=Beta platelet-derived growth factor receptor;
DE   AltName: Full=Beta-type platelet-derived growth factor receptor;
DE   AltName: Full=CD140 antigen-like family member B;
DE   AltName: Full=Platelet-derived growth factor receptor 1;
DE            Short=PDGFR-1;
DE   AltName: CD_antigen=CD140b;
DE   Flags: Precursor;
GN   Name=PDGFRB; Synonyms=PDGFR, PDGFR1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION AS PDGFB RECEPTOR,
RP   SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, AND INTERACTION WITH PDGFB.
RX   PubMed=2835772; DOI=10.1073/pnas.85.10.3435;
RA   Gronwald R.G.K., Grant F.J., Haldeman B.A., Hart C.E., O'Hara P.J.,
RA   Hagen F.S., Ross R., Bowen-Pope D.F., Murray M.J.;
RT   "Cloning and expression of a cDNA coding for the human platelet-
RT   derived growth factor receptor: evidence for more than one receptor
RT   class.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:3435-3439(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION AS PDGFB RECEPTOR,
RP   SUBCELLULAR LOCATION, GLYCOSYLATION, AUTOPHOSPHORYLATION, AND
RP   INTERACTION WITH PDGFA AND PDGFB.
RX   PubMed=2850496; DOI=10.1128/MCB.8.8.3476;
RA   Claesson-Welsh L., Eriksson A., Moren A., Severinsson L., Ek B.,
RA   Oestman A., Betsholtz C., Heldin C.-H.;
RT   "cDNA cloning and expression of a human platelet-derived growth factor
RT   (PDGF) receptor specific for B-chain-containing PDGF molecules.";
RL   Mol. Cell. Biol. 8:3476-3486(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND ALTERNATIVE SPLICING.
RX   PubMed=18593464; DOI=10.1186/ar2447;
RA   Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D.,
RA   Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.;
RT   "Novel splice variants derived from the receptor tyrosine kinase
RT   superfamily are potential therapeutics for rheumatoid arthritis.";
RL   Arthritis Res. Ther. 10:R73-R73(2008).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T.,
RA   Gomez M., Gonzales E., Goodstein D., Grigoriev I., Groza M.,
RA   Hammon N., Hawkins T., Haydu L., Israni S., Jett J., Kadner K.,
RA   Kimball H., Kobayashi A., Lopez F., Lou Y., Martinez D., Medina C.,
RA   Morgan J., Nandkeshwar R., Noonan J.P., Pitluck S., Pollard M.,
RA   Predki P., Priest J., Ramirez L., Retterer J., Rodriguez A.,
RA   Rogers S., Salamov A., Salazar A., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., Dickson M.,
RA   Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., Rokhsar D.S.,
RA   Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   PHE-180.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 548-569.
RX   PubMed=9285559; DOI=10.1038/sj.onc.1201267;
RA   Chi K.D., McPhee R.A., Wagner A.S., Dietz J.J., Pantazis P.,
RA   Goustin A.S.;
RT   "Integration of proviral DNA into the PDGF beta-receptor gene in HTLV-
RT   I-infected T-cells results in a novel tyrosine kinase product with
RT   transforming activity.";
RL   Oncogene 15:1051-1057(1997).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 559-1106 (ISOFORM 1), AND CHROMOSOMAL
RP   TRANSLOCATION WITH CEP85L.
RX   PubMed=21938754; DOI=10.1002/gcc.20930;
RA   Chmielecki J., Peifer M., Viale A., Hutchinson K., Giltnane J.,
RA   Socci N.D., Hollis C.J., Dean R.S., Yenamandra A., Jagasia M.,
RA   Kim A.S., Dave U.P., Thomas R.K., Pao W.;
RT   "Systematic screen for tyrosine kinase rearrangements identifies a
RT   novel C6orf204-PDGFRB fusion in a patient with recurrent T-ALL and an
RT   associated myeloproliferative neoplasm.";
RL   Genes Chromosomes Cancer 51:54-65(2012).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1046-1106.
RX   PubMed=2846185; DOI=10.1016/0092-8674(88)90224-3;
RA   Roberts W.M., Look A.T., Roussel M.F., Sherr C.J.;
RT   "Tandem linkage of human CSF-1 receptor (c-fms) and PDGF receptor
RT   genes.";
RL   Cell 55:655-661(1988).
RN   [9]
RP   PROTEIN SEQUENCE OF 33-47.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally
RT   verified cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [10]
RP   PHOSPHORYLATION AT TYR-751 AND TYR-857.
RX   PubMed=2550144; DOI=10.1016/0092-8674(89)90510-2;
RA   Kazlauskas A., Cooper J.A.;
RT   "Autophosphorylation of the PDGF receptor in the kinase insert region
RT   regulates interactions with cell proteins.";
RL   Cell 58:1121-1133(1989).
RN   [11]
RP   FUNCTION AS PDGFB RECEPTOR IN CELL PROLIFERATION AND CHEMOTAXIS, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=2554309; DOI=10.1073/pnas.86.21.8314;
RA   Matsui T., Pierce J.H., Fleming T.P., Greenberger J.S.,
RA   LaRochelle W.J., Ruggiero M., Aaronson S.A.;
RT   "Independent expression of human alpha or beta platelet-derived growth
RT   factor receptor cDNAs in a naive hematopoietic cell leads to
RT   functional coupling with mitogenic and chemotactic signaling
RT   pathways.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:8314-8318(1989).
RN   [12]
RP   FUNCTION IN CELL PROLIFERATION; ACTIVATION OF PLCG1 AND IN
RP   PHOSPHORYLATION OF PLCG1 AND RASA1/GAP, AND MUTAGENESIS OF TYR-751 AND
RP   TYR-857.
RX   PubMed=1653029;
RA   Kazlauskas A., Durden D.L., Cooper J.A.;
RT   "Functions of the major tyrosine phosphorylation site of the PDGF
RT   receptor beta subunit.";
RL   Cell Regul. 2:413-425(1991).
RN   [13]
RP   INTERACTION WITH PDGFRA; PDGFA AND PDGFB, FUNCTION AS RECEPTOR FOR
RP   PDGFA AND PDGFB, AND PHOSPHORYLATION AT TYR-857 AND TYR-751.
RX   PubMed=1709159;
RA   Kelly J.D., Haldeman B.A., Grant F.J., Murray M.J., Seifert R.A.,
RA   Bowen-Pope D.F., Cooper J.A., Kazlauskas A.;
RT   "Platelet-derived growth factor (PDGF) stimulates PDGF receptor
RT   subunit dimerization and intersubunit trans-phosphorylation.";
RL   J. Biol. Chem. 266:8987-8992(1991).
RN   [14]
RP   FUNCTION AS RECEPTOR FOR PDGFA AND PDGFB, SUBCELLULAR LOCATION,
RP   CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-634.
RX   PubMed=1846866; DOI=10.1083/jcb.112.3.469;
RA   Sorkin A., Westermark B., Heldin C.H., Claesson-Welsh L.;
RT   "Effect of receptor kinase inactivation on the rate of internalization
RT   and degradation of PDGF and the PDGF beta-receptor.";
RL   J. Cell Biol. 112:469-478(1991).
RN   [15]
RP   FUNCTION IN ACTIVATION OF PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY,
RP   INTERACTION WITH PIK3R1 AND RASA1, PHOSPHORYLATION AT TYR-740;
RP   TYR-751; TYR-771 AND TYR-857, AND MUTAGENESIS OF LYS-634; TYR-716;
RP   TYR-740; TYR-751; TYR-763; TYR-771; TYR-775; TYR-778 AND TYR-857.
RX   PubMed=1314164;
RA   Kashishian A., Kazlauskas A., Cooper J.A.;
RT   "Phosphorylation sites in the PDGF receptor with different
RT   specificities for binding GAP and PI3 kinase in vivo.";
RL   EMBO J. 11:1373-1382(1992).
RN   [16]
RP   FUNCTION AS PDGFB RECEPTOR IN CELL PROLIFERATION AND PHOSPHORYLATION
RP   OF PLCG1, INTERACTION WITH PLCG1, PHOSPHORYLATION AT TYR-1009 AND
RP   TYR-1021, AND MUTAGENESIS OF TYR-1009 AND TYR-1021.
RX   PubMed=1396585;
RA   Ronnstrand L., Mori S., Arridsson A.K., Eriksson A., Wernstedt C.,
RA   Hellman U., Claesson-Welsh L., Heldin C.H.;
RT   "Identification of two C-terminal autophosphorylation sites in the
RT   PDGF beta-receptor: involvement in the interaction with phospholipase
RT   C-gamma.";
RL   EMBO J. 11:3911-3919(1992).
RN   [17]
RP   UBIQUITINATION, AND DEGRADATION.
RX   PubMed=1313434;
RA   Mori S., Heldin C.H., Claesson-Welsh L.;
RT   "Ligand-induced polyubiquitination of the platelet-derived growth
RT   factor beta-receptor.";
RL   J. Biol. Chem. 267:6429-6434(1992).
RN   [18]
RP   INTERACTION WITH PIK3R1 AND RASA1, AND MUTAGENESIS OF TYR-740; TYR-751
RP   AND TYR-771.
RX   PubMed=1375321; DOI=10.1128/MCB.12.6.2534;
RA   Kazlauskas A., Kashishian A., Cooper J.A., Valius M.;
RT   "GTPase-activating protein and phosphatidylinositol 3-kinase bind to
RT   distinct regions of the platelet-derived growth factor receptor beta
RT   subunit.";
RL   Mol. Cell. Biol. 12:2534-2544(1992).
RN   [19]
RP   FUNCTION AS PDGFB RECEPTOR IN CELL PROLIFERATION, PHOSPHORYLATION AT
RP   TYR-579 AND TYR-581; INTERACTION WITH SRC, CATALYTIC ACTIVITY, AND
RP   MUTAGENESIS OF TYR-579 AND TYR-581.
RX   PubMed=7685273;
RA   Mori S., Ronnstrand L., Yokote K., Engstrom A., Courtneidge S.A.,
RA   Claesson-Welsh L., Heldin C.H.;
RT   "Identification of two juxtamembrane autophosphorylation sites in the
RT   PDGF beta-receptor; involvement in the interaction with Src family
RT   tyrosine kinases.";
RL   EMBO J. 12:2257-2264(1993).
RN   [20]
RP   INTERACTION WITH DGFA AND PDGFB.
RX   PubMed=7679113;
RA   Fretto L.J., Snape A.J., Tomlinson J.E., Seroogy J.J., Wolf D.L.,
RA   LaRochelle W.J., Giese N.A.;
RT   "Mechanism of platelet-derived growth factor (PDGF) AA, AB, and BB
RT   binding to alpha and beta PDGF receptor.";
RL   J. Biol. Chem. 268:3625-3631(1993).
RN   [21]
RP   FUNCTION IN PHOSPHORYLATION AND ACTIVATION OF PTPN11, INTERACTION WITH
RP   PTPN11; PIK3R1; PLCG1 AND RASA1, AND MUTAGENESIS OF TYR-1009.
RX   PubMed=7691811;
RA   Lechleider R.J., Sugimoto S., Bennett A.M., Kashishian A.S.,
RA   Cooper J.A., Shoelson S.E., Walsh C.T., Neel B.G.;
RT   "Activation of the SH2-containing phosphotyrosine phosphatase SH-PTP2
RT   by its binding site, phosphotyrosine 1009, on the human platelet-
RT   derived growth factor receptor.";
RL   J. Biol. Chem. 268:21478-21481(1993).
RN   [22]
RP   INTERACTION WITH NCK1 AND PIK3R1, FUNCTION IN PHOSPHORYLATION OF NCK1,
RP   AND MUTAGENESIS OF TYR-751.
RX   PubMed=7692233; DOI=10.1128/MCB.13.11.6889;
RA   Nishimura R., Li W., Kashishian A., Mondino A., Zhou M., Cooper J.,
RA   Schlessinger J.;
RT   "Two signaling molecules share a phosphotyrosine-containing binding
RT   site in the platelet-derived growth factor receptor.";
RL   Mol. Cell. Biol. 13:6889-6896(1993).
RN   [23]
RP   INTERACTION WITH SHB.
RX   PubMed=8302579;
RA   Welsh M., Mares J., Karlsson T., Lavergne C., Breant B.,
RA   Claesson-Welsh L.;
RT   "Shb is a ubiquitously expressed Src homology 2 protein.";
RL   Oncogene 9:19-27(1994).
RN   [24]
RP   INTERACTION WITH GRB7.
RX   PubMed=8940081; DOI=10.1074/jbc.271.48.30942;
RA   Yokote K., Margolis B., Heldin C.H., Claesson-Welsh L.;
RT   "Grb7 is a downstream signaling component of platelet-derived growth
RT   factor alpha- and beta-receptors.";
RL   J. Biol. Chem. 271:30942-30949(1996).
RN   [25]
RP   CHROMOSOMAL TRANSLOCATION WITH TRIP11.
RX   PubMed=9373237;
RA   Abe A., Emi N., Tanimoto M., Terasaki H., Marunouchi T., Saito H.;
RT   "Fusion of the platelet-derived growth factor receptor beta to a novel
RT   gene CEV14 in acute myelogenous leukemia after clonal evolution.";
RL   Blood 90:4271-4277(1997).
RN   [26]
RP   INTERACTION WITH GRB10, AND MUTAGENESIS OF TYR-579; TYR-581; TYR-716;
RP   TYR-740; TYR-751; TYR-771; TYR-857; TYR-1009 AND TYR-1021.
RX   PubMed=10454568; DOI=10.1128/MCB.19.9.6217;
RA   Wang J., Dai H., Yousaf N., Moussaif M., Deng Y., Boufelliga A.,
RA   Swamy O.R., Leone M.E., Riedel H.;
RT   "Grb10, a positive, stimulatory signaling adapter in platelet-derived
RT   growth factor BB-, insulin-like growth factor I-, and insulin-mediated
RT   mitogenesis.";
RL   Mol. Cell. Biol. 19:6217-6228(1999).
RN   [27]
RP   INTERACTION WITH SH2B2/APS.
RX   PubMed=9989826; DOI=10.1038/sj.onc.1202326;
RA   Yokouchi M., Wakioka T., Sakamoto H., Yasukawa H., Ohtsuka S.,
RA   Sasaki A., Ohtsubo M., Valius M., Inoue A., Komiya S., Yoshimura A.;
RT   "APS, an adaptor protein containing PH and SH2 domains, is associated
RT   with the PDGF receptor and c-Cbl and inhibits PDGF-induced
RT   mitogenesis.";
RL   Oncogene 18:759-767(1999).
RN   [28]
RP   PHOSPHORYLATION AT TYR-562; TYR-751; TYR-763; TYR-771; TYR-775;
RP   TYR-778; TYR-857; TYR-1009 AND TYR-1021, AND DEPHOSPHORYLATION AT
RP   TYR-751; TYR-857; TYR-1009 AND TYR-1021 BY PTPRJ.
RX   PubMed=10821867; DOI=10.1074/jbc.275.21.16219;
RA   Kovalenko M., Denner K., Sandstrom J., Persson C., Gross S., Jandt E.,
RA   Vilella R., Bohmer F., Ostman A.;
RT   "Site-selective dephosphorylation of the platelet-derived growth
RT   factor beta-receptor by the receptor-like protein-tyrosine phosphatase
RT   DEP-1.";
RL   J. Biol. Chem. 275:16219-16226(2000).
RN   [29]
RP   INTERACTION WITH PIK3C2B.
RX   PubMed=10805725; DOI=10.1128/MCB.20.11.3817-3830.2000;
RA   Arcaro A., Zvelebil M.J., Wallasch C., Ullrich A., Waterfield M.D.,
RA   Domin J.;
RT   "Class II phosphoinositide 3-kinases are downstream targets of
RT   activated polypeptide growth factor receptors.";
RL   Mol. Cell. Biol. 20:3817-3830(2000).
RN   [30]
RP   FUNCTION AS A RECEPTOR FOR PDGFC, AND INTERACTION WITH PDGFC.
RX   PubMed=11297552; DOI=10.1074/jbc.M101056200;
RA   Gilbertson D.G., Duff M.E., West J.W., Kelly J.D., Sheppard P.O.,
RA   Hofstrand P.D., Gao Z., Shoemaker K., Bukowski T.R., Moore M.,
RA   Feldhaus A.L., Humes J.M., Palmer T.E., Hart C.E.;
RT   "Platelet-derived growth factor C (PDGF-C), a novel growth factor that
RT   binds to PDGF alpha and beta receptor.";
RL   J. Biol. Chem. 276:27406-27414(2001).
RN   [31]
RP   FUNCTION AS A RECEPTOR FOR PDGFD.
RX   PubMed=11331881; DOI=10.1038/35074588;
RA   Bergsten E., Uutela M., Li X., Pietras K., Oestman A., Heldin C.-H.,
RA   Alitalo K., Eriksson U.;
RT   "PDGF-D is a specific, protease-activated ligand for the PDGF beta-
RT   receptor.";
RL   Nat. Cell Biol. 3:512-516(2001).
RN   [32]
RP   CHROMOSOMAL TRANSLOCATION WITH ETV6.
RX   PubMed=12181402; DOI=10.1056/NEJMoa020150;
RA   Apperley J.F., Gardembas M., Melo J.V., Russell-Jones R., Bain B.J.,
RA   Baxter E.J., Chase A., Chessells J.M., Colombat M., Dearden C.E.,
RA   Dimitrijevic S., Mahon F.-X., Marin D., Nikolova Z., Olavarria E.,
RA   Silberman S., Schultheis B., Cross N.C.P., Goldman J.M.;
RT   "Response to imatinib mesylate in patients with chronic
RT   myeloproliferative diseases with rearrangements of the platelet-
RT   derived growth factor receptor beta.";
RL   N. Engl. J. Med. 347:481-487(2002).
RN   [33]
RP   CHROMOSOMAL TRANSLOCATION WITH PDE4DIP.
RX   PubMed=12907457; DOI=10.1182/blood-2003-04-1150;
RA   Wilkinson K., Velloso E.R.P., Lopes L.F., Lee C., Aster J.C.,
RA   Shipp M.A., Aguiar R.C.T.;
RT   "Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder
RT   associated with eosinophilia: involvement of PDGFRB and response to
RT   imatinib.";
RL   Blood 102:4187-4190(2003).
RN   [34]
RP   CHROMOSOMAL TRANSLOCATION WITH SPECC1.
RX   PubMed=15087372; DOI=10.1158/0008-5472.CAN-03-4026;
RA   Morerio C., Acquila M., Rosanda C., Rapella A., Dufour C.,
RA   Locatelli F., Maserati E., Pasquali F., Panarello C.;
RT   "HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile
RT   myelomonocytic leukemia with t(5;17)(q33;p11.2).";
RL   Cancer Res. 64:2649-2651(2004).
RN   [35]
RP   CHROMOSOMAL TRANSLOCATION WITH TP53BP1, AND ENZYME REGULATION.
RX   PubMed=15492236; DOI=10.1158/0008-5472.CAN-04-2005;
RA   Grand F.H., Burgstaller S., Kuhr T., Baxter E.J., Webersinke G.,
RA   Thaler J., Chase A.J., Cross N.C.;
RT   "p53-Binding protein 1 is fused to the platelet-derived growth factor
RT   receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-
RT   responsive eosinophilic myeloproliferative disorder.";
RL   Cancer Res. 64:7216-7219(2004).
RN   [36]
RP   PHOSPHORYLATION AT TYR-579; TYR-751; TYR-771 AND TYR-1021, AND
RP   DEPHOSPHORYLATION AT TYR-579 AND TYR-1021 BY PTPN2.
RX   PubMed=14966296; DOI=10.1128/MCB.24.5.2190-2201.2004;
RA   Persson C., Saevenhed C., Bourdeau A., Tremblay M.L., Markova B.,
RA   Boehmer F.D., Haj F.G., Neel B.G., Elson A., Heldin C.H.,
RA   Roennstrand L., Ostman A., Hellberg C.;
RT   "Site-selective regulation of platelet-derived growth factor beta
RT   receptor tyrosine phosphorylation by T-cell protein tyrosine
RT   phosphatase.";
RL   Mol. Cell. Biol. 24:2190-2201(2004).
RN   [37]
RP   PHOSPHORYLATION AT TYR-579; TYR-581; TYR-716; TYR-740; TYR-771;
RP   TYR-857; TYR-1009 AND TYR-1021.
RX   PubMed=15902258; DOI=10.1038/nature03587;
RA   Choi M.H., Lee I.K., Kim G.W., Kim B.U., Han Y.H., Yu D.Y., Park H.S.,
RA   Kim K.Y., Lee J.S., Choi C., Bae Y.S., Lee B.I., Rhee S.G., Kang S.W.;
RT   "Regulation of PDGF signalling and vascular remodelling by
RT   peroxiredoxin II.";
RL   Nature 435:347-353(2005).
RN   [38]
RP   INTERACTION WITH CBL, SUBCELLULAR LOCATION, MUTAGENESIS OF TYR-1021,
RP   AND UBIQUITINATION.
RX   PubMed=17620338; DOI=10.1074/jbc.M701797200;
RA   Reddi A.L., Ying G., Duan L., Chen G., Dimri M., Douillard P.,
RA   Druker B.J., Naramura M., Band V., Band H.;
RT   "Binding of Cbl to a phospholipase Cgamma1-docking site on platelet-
RT   derived growth factor receptor beta provides a dual mechanism of
RT   negative regulation.";
RL   J. Biol. Chem. 282:29336-29347(2007).
RN   [39]
RP   FUNCTION AS PDGFD RECEPTOR.
RX   PubMed=21098708; DOI=10.1158/0008-5472.CAN-10-0511;
RA   Ustach C.V., Huang W., Conley-LaComb M.K., Lin C.Y., Che M.,
RA   Abrams J., Kim H.R.;
RT   "A novel signaling axis of matriptase/PDGF-D/ss-PDGFR in human
RT   prostate cancer.";
RL   Cancer Res. 70:9631-9640(2010).
RN   [40]
RP   FUNCTION IN PHOSPHORYLATION OF CBL; STAM; PDCD6IP/ALIX; PLCG1 AND
RP   PTPN11, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, SUBCELLULAR LOCATION,
RP   AND MUTAGENESIS OF LYS-634 AND TYR-857.
RX   PubMed=20494825; DOI=10.1016/j.cellsig.2010.05.004;
RA   Wardega P., Heldin C.H., Lennartsson J.;
RT   "Mutation of tyrosine residue 857 in the PDGF beta-receptor affects
RT   cell proliferation but not migration.";
RL   Cell. Signal. 22:1363-1368(2010).
RN   [41]
RP   FUNCTION.
RX   PubMed=20529858; DOI=10.1074/jbc.M110.102566;
RA   Mendelson K., Swendeman S., Saftig P., Blobel C.P.;
RT   "Stimulation of platelet-derived growth factor receptor beta
RT   (PDGFRbeta) activates ADAM17 and promotes metalloproteinase-dependent
RT   cross-talk between the PDGFRbeta and epidermal growth factor receptor
RT   (EGFR) signaling pathways.";
RL   J. Biol. Chem. 285:25024-25032(2010).
RN   [42]
RP   FUNCTION IN SMOOTH MUSCLE CELL PROLIFERATION AND MIGRATION.
RX   PubMed=21733313; DOI=10.1017/S0007114511002571;
RA   Kim H.J., Cha B.Y., Choi B., Lim J.S., Woo J.T., Kim J.S.;
RT   "Glyceollins inhibit platelet-derived growth factor-mediated human
RT   arterial smooth muscle cell proliferation and migration.";
RL   Br. J. Nutr. 107:24-35(2012).
RN   [43]
RP   INTERACTION WITH SHC1 AND GRB2, AND FUNCTION IN PHOSPHORYLATION OF
RP   SHC1.
RX   PubMed=8195171;
RA   Yokote K., Mori S., Hansen K., McGlade J., Pawson T., Heldin C.H.,
RA   Claesson-Welsh L.;
RT   "Direct interaction between Shc and the platelet-derived growth factor
RT   beta-receptor.";
RL   J. Biol. Chem. 269:15337-15343(1994).
RN   [44]
RP   FUNCTION IN SMOOTH MUSCLE CELL MIGRATION AND NEOINTIMA FORMATION AFTER
RP   BLOOD VESSEL INJURY, AND MUTAGENESIS OF TYR-740; TYR-751 AND TYR-1021.
RX   PubMed=21679854; DOI=10.1016/j.jacc.2011.02.037;
RA   Caglayan E., Vantler M., Leppanen O., Gerhardt F., Mustafov L.,
RA   Ten Freyhaus H., Kappert K., Odenthal M., Zimmermann W.H.,
RA   Tallquist M.D., Rosenkranz S.;
RT   "Disruption of platelet-derived growth factor-dependent
RT   phosphatidylinositol 3-kinase and phospholipase Cgamma 1 activity
RT   abolishes vascular smooth muscle cell proliferation and migration and
RT   attenuates neointima formation in vivo.";
RL   J. Am. Coll. Cardiol. 57:2527-2538(2011).
RN   [45]
RP   INVOLVEMENT IN PENTT, VARIANT PENTT ALA-665, AND CHARACTERIZATION OF
RP   VARIANT PENTT ALA-665.
RX   PubMed=26279204; DOI=10.1016/j.ajhg.2015.07.009;
RA   Johnston J.J., Sanchez-Contreras M.Y., Keppler-Noreuil K.M., Sapp J.,
RA   Crenshaw M., Finch N.A., Cormier-Daire V., Rademakers R., Sybert V.P.,
RA   Biesecker L.G.;
RT   "A point mutation in PDGFRB causes autosomal-dominant Penttinen
RT   syndrome.";
RL   Am. J. Hum. Genet. 97:465-474(2015).
RN   [46]
RP   INVOLVEMENT IN KOGS, AND VARIANT KOGS ARG-584.
RX   PubMed=25454926; DOI=10.1016/j.jpeds.2014.10.015;
RA   Takenouchi T., Yamaguchi Y., Tanikawa A., Kosaki R., Okano H.,
RA   Kosaki K.;
RT   "Novel overgrowth syndrome phenotype due to recurrent de novo PDGFRB
RT   mutation.";
RL   J. Pediatr. 166:483-486(2015).
RN   [47]
RP   CHARACTERIZATION OF VARIANTS IBGC4 PRO-658; TRP-987 AND VAL-1071, AND
RP   FUNCTION.
RX   PubMed=26599395; DOI=10.1371/journal.pone.0143407;
RA   Vanlandewijck M., Lebouvier T., Andaloussi Maee M., Nahar K.,
RA   Hornemann S., Kenkel D., Cunha S.I., Lennartsson J., Boss A.,
RA   Heldin C.H., Keller A., Betsholtz C.;
RT   "Functional characterization of germline mutations in PDGFB and PDGFRB
RT   in primary familial brain calcification.";
RL   PLoS ONE 10:E0143407-E0143407(2015).
RN   [48]
RP   REVIEW ON SIGNALING AND AUTOPHOSPHORYLATION.
RX   PubMed=9739761; DOI=10.1016/S0304-419X(98)00015-8;
RA   Heldin C.H., Ostman A., Ronnstrand L.;
RT   "Signal transduction via platelet-derived growth factor receptors.";
RL   Biochim. Biophys. Acta 1378:F79-113(1998).
RN   [49]
RP   REVIEW.
RX   PubMed=15207817; DOI=10.1016/j.cytogfr.2004.03.002;
RA   Ostman A.;
RT   "PDGF receptors-mediators of autocrine tumor growth and regulators of
RT   tumor vasculature and stroma.";
RL   Cytokine Growth Factor Rev. 15:275-286(2004).
RN   [50]
RP   REVIEW.
RX   PubMed=17419949; DOI=10.1016/S0065-230X(06)97011-0;
RA   Ostman A., Heldin C.H.;
RT   "PDGF receptors as targets in tumor treatment.";
RL   Adv. Cancer Res. 97:247-274(2007).
RN   [51]
RP   REVIEW ON FUNCTION; LIGANDS; ROLE IN DEVELOPMENT AND DISEASE AND
RP   ACTIVATION OF SIGNALING PATHWAYS.
RX   PubMed=18483217; DOI=10.1101/gad.1653708;
RA   Andrae J., Gallini R., Betsholtz C.;
RT   "Role of platelet-derived growth factors in physiology and medicine.";
RL   Genes Dev. 22:1276-1312(2008).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (1.79 ANGSTROMS) OF 751-755 IN COMPLEX WITH
RP   PIK3R1, AND COMPARISON WITH NMR ANALYSIS.
RX   PubMed=11567151; DOI=10.1107/S0907444901012434;
RA   Pauptit R.A., Dennis C.A., Derbyshire D.J., Breeze A.L., Weston S.A.,
RA   Rowsell S., Murshudov G.N.;
RT   "NMR trial models: experiences with the colicin immunity protein Im7
RT   and the p85alpha C-terminal SH2-peptide complex.";
RL   Acta Crystallogr. D 57:1397-1404(2001).
RN   [53]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 1102-1106 IN COMPLEX WITH
RP   SLC9A3R1, AND INTERACTION WITH SLC9A3R1.
RX   PubMed=11882663; DOI=10.1074/jbc.M201507200;
RA   Karthikeyan S., Leung T., Ladias J.A.A.;
RT   "Structural determinants of the Na+/H+ exchanger regulatory factor
RT   interaction with the beta 2 adrenergic and platelet-derived growth
RT   factor receptors.";
RL   J. Biol. Chem. 277:18973-18978(2002).
RN   [54]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 33-314 IN COMPLEX WITH PDGFB,
RP   SUBUNIT, GLYCOSYLATION AT ASN-45; ASN-89; ASN-103; ASN-215; ASN-230;
RP   ASN-292 AND ASN-307, AND DISULFIDE BONDS.
RX   PubMed=20534510; DOI=10.1073/pnas.1000806107;
RA   Shim A.H., Liu H., Focia P.J., Chen X., Lin P.C., He X.;
RT   "Structures of a platelet-derived growth factor/propeptide complex and
RT   a platelet-derived growth factor/receptor complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:11307-11312(2010).
RN   [55]
RP   VARIANTS [LARGE SCALE ANALYSIS] PHE-29; LYS-282; LYS-485; HIS-589;
RP   TYR-718 AND ILE-882.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [56]
RP   VARIANT IMF1 THR-660.
RX   PubMed=23731542; DOI=10.1016/j.ajhg.2013.04.024;
RA   Martignetti J.A., Tian L., Li D., Ramirez M.C., Camacho-Vanegas O.,
RA   Camacho S.C., Guo Y., Zand D.J., Bernstein A.M., Masur S.K., Kim C.E.,
RA   Otieno F.G., Hou C., Abdel-Magid N., Tweddale B., Metry D.,
RA   Fournet J.C., Papp E., McPherson E.W., Zabel C., Vaksmann G.,
RA   Morisot C., Keating B., Sleiman P.M., Cleveland J.A., Everman D.B.,
RA   Zackai E., Hakonarson H.;
RT   "Mutations in PDGFRB cause autosomal-dominant infantile
RT   myofibromatosis.";
RL   Am. J. Hum. Genet. 92:1001-1007(2013).
RN   [57]
RP   VARIANT IMF1 CYS-561.
RX   PubMed=23731537; DOI=10.1016/j.ajhg.2013.04.026;
RA   Cheung Y.H., Gayden T., Campeau P.M., Leduc C.A., Russo D.,
RA   Nguyen V.H., Guo J., Qi M., Guan Y., Albrecht S., Moroz B.,
RA   Eldin K.W., Lu J.T., Schwartzentruber J., Malkin D., Berghuis A.M.,
RA   Emil S., Gibbs R.A., Burk D.L., Vanstone M., Lee B.H., Orchard D.,
RA   Boycott K.M., Chung W.K., Jabado N.;
RT   "A recurrent PDGFRB mutation causes familial infantile
RT   myofibromatosis.";
RL   Am. J. Hum. Genet. 92:996-1000(2013).
RN   [58]
RP   VARIANTS IBGC4 PRO-658; TRP-987 AND VAL-1071.
RX   PubMed=24065723; DOI=10.1093/brain/awt255;
RG   French IBGC Study Group;
RA   Nicolas G., Pottier C., Charbonnier C., Guyant-Marechal L., Le Ber I.,
RA   Pariente J., Labauge P., Ayrignac X., Defebvre L., Maltete D.,
RA   Martinaud O., Lefaucheur R., Guillin O., Wallon D., Chaumette B.,
RA   Rondepierre P., Derache N., Fromager G., Schaeffer S., Krystkowiak P.,
RA   Verny C., Jurici S., Sauvee M., Verin M., Lebouvier T., Rouaud O.,
RA   Thauvin-Robinet C., Rousseau S., Rovelet-Lecrux A., Frebourg T.,
RA   Campion D., Hannequin D.;
RT   "Phenotypic spectrum of probable and genetically-confirmed idiopathic
RT   basal ganglia calcification.";
RL   Brain 136:3395-3407(2013).
RN   [59]
RP   VARIANTS IBGC4 PRO-658 AND TRP-987.
RX   PubMed=23255827; DOI=10.1212/WNL.0b013e31827ccf34;
RA   Nicolas G., Pottier C., Maltete D., Coutant S., Rovelet-Lecrux A.,
RA   Legallic S., Rousseau S., Vaschalde Y., Guyant-Marechal L.,
RA   Augustin J., Martinaud O., Defebvre L., Krystkowiak P., Pariente J.,
RA   Clanet M., Labauge P., Ayrignac X., Lefaucheur R., Le Ber I.,
RA   Frebourg T., Hannequin D., Campion D.;
RT   "Mutation of the PDGFRB gene as a cause of idiopathic basal ganglia
RT   calcification.";
RL   Neurology 80:181-187(2013).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as cell-surface
CC       receptor for homodimeric PDGFB and PDGFD and for heterodimers
CC       formed by PDGFA and PDGFB, and plays an essential role in the
CC       regulation of embryonic development, cell proliferation, survival,
CC       differentiation, chemotaxis and migration. Plays an essential role
CC       in blood vessel development by promoting proliferation, migration
CC       and recruitment of pericytes and smooth muscle cells to
CC       endothelial cells. Plays a role in the migration of vascular
CC       smooth muscle cells and the formation of neointima at vascular
CC       injury sites. Required for normal development of the
CC       cardiovascular system. Required for normal recruitment of
CC       pericytes (mesangial cells) in the kidney glomerulus, and for
CC       normal formation of a branched network of capillaries in kidney
CC       glomeruli. Promotes rearrangement of the actin cytoskeleton and
CC       the formation of membrane ruffles. Binding of its cognate ligands
CC       - homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or
CC       homodimeric PDGFD -leads to the activation of several signaling
CC       cascades; the response depends on the nature of the bound ligand
CC       and is modulated by the formation of heterodimers between PDGFRA
CC       and PDGFRB. Phosphorylates PLCG1, PIK3R1, PTPN11, RASA1/GAP, CBL,
CC       SHC1 and NCK1. Activation of PLCG1 leads to the production of the
CC       cellular signaling molecules diacylglycerol and inositol 1,4,5-
CC       trisphosphate, mobilization of cytosolic Ca(2+) and the activation
CC       of protein kinase C. Phosphorylation of PIK3R1, the regulatory
CC       subunit of phosphatidylinositol 3-kinase, leads to the activation
CC       of the AKT1 signaling pathway. Phosphorylation of SHC1, or of the
CC       C-terminus of PTPN11, creates a binding site for GRB2, resulting
CC       in the activation of HRAS, RAF1 and down-stream MAP kinases,
CC       including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation
CC       and activation of SRC family kinases. Promotes phosphorylation of
CC       PDCD6IP/ALIX and STAM. Receptor signaling is down-regulated by
CC       protein phosphatases that dephosphorylate the receptor and its
CC       down-stream effectors, and by rapid internalization of the
CC       activated receptor. {ECO:0000269|PubMed:11297552,
CC       ECO:0000269|PubMed:11331881, ECO:0000269|PubMed:1314164,
CC       ECO:0000269|PubMed:1396585, ECO:0000269|PubMed:1653029,
CC       ECO:0000269|PubMed:1709159, ECO:0000269|PubMed:1846866,
CC       ECO:0000269|PubMed:20494825, ECO:0000269|PubMed:20529858,
CC       ECO:0000269|PubMed:21098708, ECO:0000269|PubMed:21679854,
CC       ECO:0000269|PubMed:21733313, ECO:0000269|PubMed:2554309,
CC       ECO:0000269|PubMed:26599395, ECO:0000269|PubMed:2835772,
CC       ECO:0000269|PubMed:2850496, ECO:0000269|PubMed:7685273,
CC       ECO:0000269|PubMed:7691811, ECO:0000269|PubMed:7692233,
CC       ECO:0000269|PubMed:8195171}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:1846866,
CC       ECO:0000269|PubMed:20494825, ECO:0000269|PubMed:7685273}.
CC   -!- ENZYME REGULATION: Present in an inactive conformation in the
CC       absence of bound ligand. Binding of PDGFB and/or PDGFD leads to
CC       dimerization and activation by autophosphorylation on tyrosine
CC       residues. Inhibited by imatinib. {ECO:0000269|PubMed:15492236}.
CC   -!- SUBUNIT: Interacts with homodimeric PDGFB and PDGFD, and with
CC       heterodimers formed by PDGFA and PDGFB. May also interact with
CC       homodimeric PDGFC. Monomer in the absence of bound ligand.
CC       Interaction with homodimeric PDGFB, heterodimers formed by PDGFA
CC       and PDGFB or homodimeric PDGFD, leads to receptor dimerization,
CC       where both PDGFRA homodimers and heterodimers with PDGFRB are
CC       observed. Interacts with SH2B2/APS. Interacts directly (tyrosine
CC       phosphorylated) with SHB. Interacts (tyrosine phosphorylated) with
CC       PIK3R1 and RASA1. Interacts (tyrosine phosphorylated) with CBL.
CC       Interacts (tyrosine phosphorylated) with SRC and SRC family
CC       kinases. Interacts (tyrosine phosphorylated) with PIK3C2B, maybe
CC       indirectly. Interacts (tyrosine phosphorylated) with SHC1, GRB7,
CC       GRB10 and NCK1. Interaction with GRB2 is mediated by SHC1.
CC       Interacts (via C-terminus) with SLC9A3R1.
CC       {ECO:0000269|PubMed:10454568, ECO:0000269|PubMed:10805725,
CC       ECO:0000269|PubMed:11297552, ECO:0000269|PubMed:11567151,
CC       ECO:0000269|PubMed:11882663, ECO:0000269|PubMed:1314164,
CC       ECO:0000269|PubMed:1375321, ECO:0000269|PubMed:1396585,
CC       ECO:0000269|PubMed:1709159, ECO:0000269|PubMed:17620338,
CC       ECO:0000269|PubMed:20534510, ECO:0000269|PubMed:2835772,
CC       ECO:0000269|PubMed:2850496, ECO:0000269|PubMed:7679113,
CC       ECO:0000269|PubMed:7691811, ECO:0000269|PubMed:7692233,
CC       ECO:0000269|PubMed:8195171, ECO:0000269|PubMed:8302579,
CC       ECO:0000269|PubMed:8940081, ECO:0000269|PubMed:9989826}.
CC   -!- INTERACTION:
CC       P0CK45:E5 (xeno); NbExp=2; IntAct=EBI-641237, EBI-7015490;
CC       P06241:FYN; NbExp=3; IntAct=EBI-641237, EBI-515315;
CC       Q14451:GRB7; NbExp=4; IntAct=EBI-641237, EBI-970191;
CC       Q53G59:KLHL12; NbExp=5; IntAct=EBI-641237, EBI-740929;
CC       P01127:PDGFB; NbExp=13; IntAct=EBI-641237, EBI-1554925;
CC       P23727:PIK3R1 (xeno); NbExp=6; IntAct=EBI-641237, EBI-520244;
CC       P27986:PIK3R1; NbExp=19; IntAct=EBI-641237, EBI-79464;
CC       P08487:PLCG1 (xeno); NbExp=3; IntAct=EBI-641237, EBI-8013886;
CC       P19174:PLCG1; NbExp=5; IntAct=EBI-641237, EBI-79387;
CC       P60484:PTEN; NbExp=3; IntAct=EBI-641237, EBI-696162;
CC       P18031:PTPN1; NbExp=3; IntAct=EBI-641237, EBI-968788;
CC       Q06124:PTPN11; NbExp=8; IntAct=EBI-641237, EBI-297779;
CC       Q05209:PTPN12; NbExp=3; IntAct=EBI-641237, EBI-2266035;
CC       Q12913:PTPRJ; NbExp=4; IntAct=EBI-641237, EBI-2264500;
CC       P04049:RAF1; NbExp=2; IntAct=EBI-641237, EBI-365996;
CC       P20936:RASA1; NbExp=3; IntAct=EBI-641237, EBI-1026476;
CC       Q13239:SLA; NbExp=4; IntAct=EBI-641237, EBI-726214;
CC       O14745:SLC9A3R1; NbExp=5; IntAct=EBI-641237, EBI-349787;
CC       Q15654:TRIP6; NbExp=3; IntAct=EBI-641237, EBI-742327;
CC       P25020:V-SRC (xeno); NbExp=4; IntAct=EBI-641237, EBI-8636140;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Cytoplasmic vesicle. Lysosome lumen. Note=After ligand
CC       binding, the autophosphorylated receptor is ubiquitinated and
CC       internalized, leading to its degradation.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P09619-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P09619-2; Sequence=VSP_056008, VSP_056009;
CC   -!- PTM: Autophosphorylated on tyrosine residues upon ligand binding.
CC       Autophosphorylation occurs in trans, i.e. one subunit of the
CC       dimeric receptor phosphorylates tyrosine residues on the other
CC       subunit. Phosphorylation at Tyr-579, and to a lesser degree, at
CC       Tyr-581, is important for interaction with SRC family kinases.
CC       Phosphorylation at Tyr-740 and Tyr-751 is important for
CC       interaction with PIK3R1. Phosphorylation at Tyr-751 is important
CC       for interaction with NCK1. Phosphorylation at Tyr-771 and Tyr-857
CC       is important for interaction with RASA1/GAP. Phosphorylation at
CC       Tyr-857 is important for efficient phosphorylation of PLCG1 and
CC       PTPN11, resulting in increased phosphorylation of AKT1, MAPK1/ERK2
CC       and/or MAPK3/ERK1, PDCD6IP/ALIX and STAM, and in increased cell
CC       proliferation. Phosphorylation at Tyr-1009 is important for
CC       interaction with PTPN11. Phosphorylation at Tyr-1009 and Tyr-1021
CC       is important for interaction with PLCG1. Phosphorylation at Tyr-
CC       1021 is important for interaction with CBL; PLCG1 and CBL compete
CC       for the same binding site. Dephosphorylated by PTPRJ at Tyr-751,
CC       Tyr-857, Tyr-1009 and Tyr-1021. Dephosphorylated by PTPN2 at Tyr-
CC       579 and Tyr-1021. {ECO:0000269|PubMed:10821867,
CC       ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1396585,
CC       ECO:0000269|PubMed:14966296, ECO:0000269|PubMed:15902258,
CC       ECO:0000269|PubMed:1709159, ECO:0000269|PubMed:2550144,
CC       ECO:0000269|PubMed:7685273}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:20534510,
CC       ECO:0000269|PubMed:2850496}.
CC   -!- PTM: Ubiquitinated. After autophosphorylation, the receptor is
CC       polyubiquitinated, leading to its degradation.
CC       {ECO:0000269|PubMed:1313434, ECO:0000269|PubMed:17620338}.
CC   -!- DISEASE: Note=A chromosomal aberration involving PDGFRB is found
CC       in a form of chronic myelomonocytic leukemia (CMML). Translocation
CC       t(5;12)(q33;p13) with EVT6/TEL. It is characterized by abnormal
CC       clonal myeloid proliferation and by progression to acute
CC       myelogenous leukemia (AML).
CC   -!- DISEASE: Myeloproliferative disorder chronic with eosinophilia
CC       (MPE) [MIM:131440]: A hematologic disorder characterized by
CC       malignant eosinophils proliferation. Note=The gene represented in
CC       this entry may be involved in disease pathogenesis. Chromosomal
CC       aberrations involving PDGFRB have been found in many instances of
CC       chronic myeloproliferative disorder with eosinophilia.
CC       Translocation t(5;12) with ETV6 on chromosome 12 creating an
CC       PDGFRB-ETV6 fusion protein (PubMed:12181402). Translocation
CC       t(5;15)(q33;q22) with TP53BP1 creating a PDGFRB-TP53BP1 fusion
CC       protein (PubMed:15492236). Translocation t(1;5)(q23;q33) that
CC       forms a PDE4DIP-PDGFRB fusion protein (PubMed:12907457).
CC       Translocation t(5;6)(q33-34;q23) with CEP85L that fuses the 5'-end
CC       of CEP85L (isoform 4) to the 3'-end of PDGFRB (PubMed:21938754).
CC       {ECO:0000269|PubMed:12181402, ECO:0000269|PubMed:12907457,
CC       ECO:0000269|PubMed:15492236, ECO:0000269|PubMed:21938754}.
CC   -!- DISEASE: Leukemia, acute myelogenous (AML) [MIM:601626]: A subtype
CC       of acute leukemia, a cancer of the white blood cells. AML is a
CC       malignant disease of bone marrow characterized by maturational
CC       arrest of hematopoietic precursors at an early stage of
CC       development. Clonal expansion of myeloid blasts occurs in bone
CC       marrow, blood, and other tissue. Myelogenous leukemias develop
CC       from changes in cells that normally produce neutrophils,
CC       basophils, eosinophils and monocytes. Note=The gene represented in
CC       this entry may be involved in disease pathogenesis. A chromosomal
CC       aberration involving PDGFRB has been found in a patient with AML.
CC       Translocation t(5;14)(q33;q32) with TRIP11 (PubMed:9373237).
CC       {ECO:0000269|PubMed:9373237}.
CC   -!- DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An
CC       aggressive pediatric myelodysplastic syndrome/myeloproliferative
CC       disorder characterized by malignant transformation in the
CC       hematopoietic stem cell compartment with proliferation of
CC       differentiated progeny. Patients have splenomegaly, enlarged lymph
CC       nodes, rashes, and hemorrhages. Note=The gene represented in this
CC       entry may be involved in disease pathogenesis. A chromosomal
CC       aberration involving PDGFRB has been found in a patient with JMML.
CC       Translocation t(5;17)(q33;p11.2) with SPECC1 (PubMed:15087372).
CC       {ECO:0000269|PubMed:15087372}.
CC   -!- DISEASE: Basal ganglia calcification, idiopathic, 4 (IBGC4)
CC       [MIM:615007]: A form of basal ganglia calcification, an autosomal
CC       dominant condition characterized by symmetric calcification in the
CC       basal ganglia and other brain regions. Affected individuals can
CC       either be asymptomatic or show a wide spectrum of neuropsychiatric
CC       symptoms, including parkinsonism, dystonia, tremor, ataxia,
CC       dementia, psychosis, seizures, and chronic headache. Serum levels
CC       of calcium, phosphate, alkaline phosphatase and parathyroid
CC       hormone are normal. The neuropathological hallmark of the disease
CC       is vascular and pericapillary calcification, mainly of calcium
CC       phosphate, in the affected brain areas.
CC       {ECO:0000269|PubMed:23255827, ECO:0000269|PubMed:24065723,
CC       ECO:0000269|PubMed:26599395}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Myofibromatosis, infantile 1 (IMF1) [MIM:228550]: A rare
CC       mesenchymal disorder characterized by the development of benign
CC       tumors in the skin, striated muscles, bones, and, more rarely,
CC       visceral organs. Subcutaneous or soft tissue nodules commonly
CC       involve the skin of the head, neck, and trunk. Skeletal and
CC       muscular lesions occur in about half of the patients. Lesions may
CC       be solitary or multicentric, and they may be present at birth or
CC       become apparent in early infancy or occasionally in adult life.
CC       Visceral lesions are associated with high morbidity and mortality.
CC       {ECO:0000269|PubMed:23731537, ECO:0000269|PubMed:23731542}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Kosaki overgrowth syndrome (KOGS) [MIM:616592]: A
CC       syndrome characterized by somatic overgrowth, distinctive facial
CC       features, hyperelastic and fragile skin, and progressive
CC       neurologic deterioration with white matter lesions on brain
CC       imaging. {ECO:0000269|PubMed:25454926}. Note=The disease is caused
CC       by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Premature aging syndrome, Penttinen type (PENTT)
CC       [MIM:601812]: A syndrome characterized by a prematurely aged
CC       appearance with lipoatrophy, epidermal and dermal atrophy along
CC       with hypertrophic lesions that resemble scars, thin hair,
CC       proptosis, underdeveloped cheekbones, and marked acro-osteolysis.
CC       {ECO:0000269|PubMed:26279204}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. CSF-1/PDGF receptor subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PDGFRBID21ch5q32.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J03278; AAA60049.1; -; mRNA.
DR   EMBL; M21616; AAA36427.1; -; mRNA.
DR   EMBL; EU826595; ACF47631.1; -; mRNA.
DR   EMBL; AC005895; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC011382; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC032224; AAH32224.1; -; mRNA.
DR   EMBL; U33172; AAC51675.1; -; Genomic_DNA.
DR   CCDS; CCDS4303.1; -. [P09619-1]
DR   PIR; A28206; PFHUGB.
DR   RefSeq; NP_002600.1; NM_002609.3. [P09619-1]
DR   RefSeq; XP_011535960.1; XM_011537658.1. [P09619-1]
DR   RefSeq; XP_011535961.1; XM_011537659.1. [P09619-1]
DR   UniGene; Hs.509067; -.
DR   PDB; 1GQ5; X-ray; 2.20 A; A=1102-1106.
DR   PDB; 1H9O; X-ray; 1.79 A; B=751-755.
DR   PDB; 1LWP; Model; -; A=600-962.
DR   PDB; 1SHA; X-ray; 1.50 A; B=751-755.
DR   PDB; 2L6W; NMR; -; A/B=526-563.
DR   PDB; 2PLD; NMR; -; B=1018-1029.
DR   PDB; 2PLE; NMR; -; B=1018-1029.
DR   PDB; 3MJG; X-ray; 2.30 A; X/Y=33-314.
DR   PDBsum; 1GQ5; -.
DR   PDBsum; 1H9O; -.
DR   PDBsum; 1LWP; -.
DR   PDBsum; 1SHA; -.
DR   PDBsum; 2L6W; -.
DR   PDBsum; 2PLD; -.
DR   PDBsum; 2PLE; -.
DR   PDBsum; 3MJG; -.
DR   ProteinModelPortal; P09619; -.
DR   SMR; P09619; -.
DR   BioGrid; 111185; 73.
DR   DIP; DIP-558N; -.
DR   IntAct; P09619; 81.
DR   MINT; MINT-148093; -.
DR   STRING; 9606.ENSP00000261799; -.
DR   BindingDB; P09619; -.
DR   ChEMBL; CHEMBL1913; -.
DR   DrugBank; DB00102; Becaplermin.
DR   DrugBank; DB01254; Dasatinib.
DR   DrugBank; DB00619; Imatinib.
DR   DrugBank; DB06589; Pazopanib.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugBank; DB00398; Sorafenib.
DR   DrugBank; DB01268; Sunitinib.
DR   DrugBank; DB05146; XL820.
DR   DrugBank; DB05014; XL999.
DR   GuidetoPHARMACOLOGY; 1804; -.
DR   iPTMnet; P09619; -.
DR   PhosphoSitePlus; P09619; -.
DR   BioMuta; PDGFRB; -.
DR   DMDM; 129890; -.
DR   EPD; P09619; -.
DR   MaxQB; P09619; -.
DR   PaxDb; P09619; -.
DR   PeptideAtlas; P09619; -.
DR   PRIDE; P09619; -.
DR   DNASU; 5159; -.
DR   Ensembl; ENST00000261799; ENSP00000261799; ENSG00000113721. [P09619-1]
DR   GeneID; 5159; -.
DR   KEGG; hsa:5159; -.
DR   UCSC; uc003lro.4; human. [P09619-1]
DR   CTD; 5159; -.
DR   DisGeNET; 5159; -.
DR   GeneCards; PDGFRB; -.
DR   GeneReviews; PDGFRB; -.
DR   HGNC; HGNC:8804; PDGFRB.
DR   HPA; CAB003842; -.
DR   HPA; CAB018144; -.
DR   HPA; HPA028499; -.
DR   MalaCards; PDGFRB; -.
DR   MIM; 131440; phenotype.
DR   MIM; 173410; gene.
DR   MIM; 228550; phenotype.
DR   MIM; 601626; phenotype.
DR   MIM; 601812; phenotype.
DR   MIM; 607785; phenotype.
DR   MIM; 615007; phenotype.
DR   MIM; 616592; phenotype.
DR   neXtProt; NX_P09619; -.
DR   OpenTargets; ENSG00000113721; -.
DR   Orphanet; 1980; Bilateral striopallidodentate calcinosis.
DR   Orphanet; 98823; Chronic myelomonocytic leukemia.
DR   Orphanet; 2591; Infantile myofibromatosis.
DR   Orphanet; 168950; Myeloid neoplasm associated with PDGFRB rearrangement.
DR   Orphanet; 314950; Primary hypereosinophilic syndrome.
DR   Orphanet; 86830; Unclassified chronic myeloproliferative disease.
DR   PharmGKB; PA33148; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118923; -.
DR   HOGENOM; HOG000112009; -.
DR   HOVERGEN; HBG004335; -.
DR   InParanoid; P09619; -.
DR   KO; K05089; -.
DR   OMA; APYDNYV; -.
DR   OrthoDB; EOG091G01TL; -.
DR   PhylomeDB; P09619; -.
DR   TreeFam; TF325768; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-186763; Downstream signal transduction.
DR   Reactome; R-HSA-186797; Signaling by PDGF.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   SignaLink; P09619; -.
DR   SIGNOR; P09619; -.
DR   ChiTaRS; PDGFRB; human.
DR   EvolutionaryTrace; P09619; -.
DR   GeneWiki; PDGFRB; -.
DR   GenomeRNAi; 5159; -.
DR   PRO; PR:P09619; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; ENSG00000113721; -.
DR   CleanEx; HS_PDGFRB; -.
DR   ExpressionAtlas; P09619; baseline and differential.
DR   Genevisible; P09619; HS.
DR   GO; GO:0016324; C:apical plasma membrane; ISS:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IEA:UniProtKB-KW.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0031226; C:intrinsic component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043202; C:lysosomal lumen; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL.
DR   GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; IEA:Ensembl.
DR   GO; GO:0046934; F:phosphatidylinositol-4,5-bisphosphate 3-kinase activity; TAS:Reactome.
DR   GO; GO:0004992; F:platelet activating factor receptor activity; TAS:ProtInc.
DR   GO; GO:0005019; F:platelet-derived growth factor beta-receptor activity; IDA:UniProtKB.
DR   GO; GO:0048407; F:platelet-derived growth factor binding; IDA:UniProtKB.
DR   GO; GO:0005161; F:platelet-derived growth factor receptor binding; IPI:BHF-UCL.
DR   GO; GO:0005017; F:platelet-derived growth factor-activated receptor activity; TAS:ProtInc.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0005088; F:Ras guanyl-nucleotide exchange factor activity; TAS:Reactome.
DR   GO; GO:0005102; F:receptor binding; IPI:UniProtKB.
DR   GO; GO:0038085; F:vascular endothelial growth factor binding; IPI:BHF-UCL.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0035909; P:aorta morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0055003; P:cardiac myofibril assembly; ISS:UniProtKB.
DR   GO; GO:0060326; P:cell chemotaxis; IDA:UniProtKB.
DR   GO; GO:0016477; P:cell migration; IMP:UniProtKB.
DR   GO; GO:0060981; P:cell migration involved in coronary angiogenesis; ISS:UniProtKB.
DR   GO; GO:0035441; P:cell migration involved in vasculogenesis; ISS:UniProtKB.
DR   GO; GO:0006024; P:glycosaminoglycan biosynthetic process; IEA:Ensembl.
DR   GO; GO:0048839; P:inner ear development; IEA:Ensembl.
DR   GO; GO:0060437; P:lung growth; IEA:Ensembl.
DR   GO; GO:0008584; P:male gonad development; IEA:Ensembl.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0072278; P:metanephric comma-shaped body morphogenesis; IEA:Ensembl.
DR   GO; GO:0072277; P:metanephric glomerular capillary formation; ISS:UniProtKB.
DR   GO; GO:0072262; P:metanephric glomerular mesangial cell proliferation involved in metanephros development; ISS:UniProtKB.
DR   GO; GO:0035789; P:metanephric mesenchymal cell migration; IEA:Ensembl.
DR   GO; GO:0072075; P:metanephric mesenchyme development; IEA:Ensembl.
DR   GO; GO:0072284; P:metanephric S-shaped body morphogenesis; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:2000587; P:negative regulation of platelet-derived growth factor receptor-beta signaling pathway; TAS:Reactome.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0046488; P:phosphatidylinositol metabolic process; IMP:UniProtKB.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; IMP:UniProtKB.
DR   GO; GO:0048008; P:platelet-derived growth factor receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0035791; P:platelet-derived growth factor receptor-beta signaling pathway; IMP:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0090280; P:positive regulation of calcium ion import; ISS:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:0038091; P:positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0050921; P:positive regulation of chemotaxis; ISS:UniProtKB.
DR   GO; GO:0032967; P:positive regulation of collagen biosynthetic process; IEA:Ensembl.
DR   GO; GO:2000573; P:positive regulation of DNA biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; IEA:Ensembl.
DR   GO; GO:2000491; P:positive regulation of hepatic stellate cell activation; IEA:Ensembl.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; ISS:UniProtKB.
DR   GO; GO:0035793; P:positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway; ISS:UniProtKB.
DR   GO; GO:0045840; P:positive regulation of mitotic nuclear division; ISS:UniProtKB.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; IDA:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; ISS:UniProtKB.
DR   GO; GO:0010863; P:positive regulation of phospholipase C activity; IDA:UniProtKB.
DR   GO; GO:0032516; P:positive regulation of phosphoprotein phosphatase activity; IDA:UniProtKB.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; ISS:UniProtKB.
DR   GO; GO:0035025; P:positive regulation of Rho protein signal transduction; IEA:Ensembl.
DR   GO; GO:0014911; P:positive regulation of smooth muscle cell migration; IMP:UniProtKB.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0032956; P:regulation of actin cytoskeleton organization; ISS:BHF-UCL.
DR   GO; GO:0014066; P:regulation of phosphatidylinositol 3-kinase signaling; TAS:Reactome.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0043627; P:response to estrogen; IEA:Ensembl.
DR   GO; GO:0034405; P:response to fluid shear stress; IEA:Ensembl.
DR   GO; GO:0042542; P:response to hydrogen peroxide; IEA:Ensembl.
DR   GO; GO:0055093; P:response to hyperoxia; IEA:Ensembl.
DR   GO; GO:0032526; P:response to retinoic acid; IEA:Ensembl.
DR   GO; GO:0009636; P:response to toxic substance; IEA:Ensembl.
DR   GO; GO:0061298; P:retina vasculature development in camera-type eye; ISS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; IDA:UniProtKB.
DR   GO; GO:0071670; P:smooth muscle cell chemotaxis; ISS:BHF-UCL.
DR   GO; GO:0042060; P:wound healing; IEA:Ensembl.
DR   Gene3D; 2.60.40.10; -; 5.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR013151; Immunoglobulin.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR027288; PGFRB.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016243; Tyr_kinase_CSF1/PDGF_rcpt.
DR   InterPro; IPR001824; Tyr_kinase_rcpt_3_CS.
DR   Pfam; PF07679; I-set; 1.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF500948; Beta-PDGF_receptor; 1.
DR   PIRSF; PIRSF000615; TyrPK_CSF1-R; 1.
DR   SMART; SM00409; IG; 3.
DR   SMART; SM00408; IGc2; 3.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 3.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS50835; IG_LIKE; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Chemotaxis; Chromosomal rearrangement; Complete proteome;
KW   Cytoplasmic vesicle; Developmental protein; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Glycoprotein; Immunoglobulin domain;
KW   Kinase; Lysosome; Membrane; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Proto-oncogene; Receptor; Reference proteome; Repeat;
KW   Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     32       {ECO:0000269|PubMed:15340161}.
FT   CHAIN        33   1106       Platelet-derived growth factor receptor
FT                                beta.
FT                                /FTId=PRO_0000016757.
FT   TOPO_DOM     33    532       Extracellular. {ECO:0000255}.
FT   TRANSMEM    533    553       Helical. {ECO:0000255}.
FT   TOPO_DOM    554   1106       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       33    120       Ig-like C2-type 1.
FT   DOMAIN      129    210       Ig-like C2-type 2.
FT   DOMAIN      214    309       Ig-like C2-type 3.
FT   DOMAIN      331    403       Ig-like C2-type 4.
FT   DOMAIN      416    524       Ig-like C2-type 5.
FT   DOMAIN      600    962       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     606    614       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    826    826       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     634    634       ATP. {ECO:0000305}.
FT   SITE        527    528       Breakpoint for insertion to form PDE4DIP-
FT                                PDGFRB fusion protein.
FT   SITE        527    528       Breakpoint for translocation to form
FT                                TRIP11-PDGFRB.
FT   SITE        558    559       Breakpoint for translocation to form the
FT                                CEP85L-PDGFRB fusion protein.
FT   MOD_RES     562    562       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10821867}.
FT   MOD_RES     579    579       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:14966296,
FT                                ECO:0000269|PubMed:15902258,
FT                                ECO:0000269|PubMed:7685273}.
FT   MOD_RES     581    581       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15902258,
FT                                ECO:0000269|PubMed:7685273}.
FT   MOD_RES     686    686       Phosphotyrosine; by ABL1 and ABL2.
FT                                {ECO:0000250}.
FT   MOD_RES     716    716       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15902258}.
FT   MOD_RES     740    740       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:1314164,
FT                                ECO:0000269|PubMed:15902258}.
FT   MOD_RES     751    751       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10821867,
FT                                ECO:0000269|PubMed:1314164,
FT                                ECO:0000269|PubMed:14966296,
FT                                ECO:0000269|PubMed:1709159,
FT                                ECO:0000269|PubMed:2550144}.
FT   MOD_RES     763    763       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10821867}.
FT   MOD_RES     771    771       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10821867,
FT                                ECO:0000269|PubMed:1314164,
FT                                ECO:0000269|PubMed:14966296,
FT                                ECO:0000269|PubMed:15902258}.
FT   MOD_RES     775    775       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10821867}.
FT   MOD_RES     778    778       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10821867}.
FT   MOD_RES     857    857       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10821867,
FT                                ECO:0000269|PubMed:1314164,
FT                                ECO:0000269|PubMed:15902258,
FT                                ECO:0000269|PubMed:1709159,
FT                                ECO:0000269|PubMed:2550144}.
FT   MOD_RES     934    934       Phosphotyrosine; by ABL1 and ABL2.
FT                                {ECO:0000250}.
FT   MOD_RES     970    970       Phosphotyrosine; by ABL1 and ABL2.
FT                                {ECO:0000250}.
FT   MOD_RES    1009   1009       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10821867,
FT                                ECO:0000269|PubMed:1396585,
FT                                ECO:0000269|PubMed:15902258}.
FT   MOD_RES    1021   1021       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10821867,
FT                                ECO:0000269|PubMed:1396585,
FT                                ECO:0000269|PubMed:14966296,
FT                                ECO:0000269|PubMed:15902258}.
FT   CARBOHYD     45     45       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD     89     89       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:20534510}.
FT   CARBOHYD    103    103       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:20534510}.
FT   CARBOHYD    215    215       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:20534510}.
FT   CARBOHYD    230    230       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:20534510}.
FT   CARBOHYD    292    292       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:20534510}.
FT   CARBOHYD    307    307       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:20534510}.
FT   CARBOHYD    354    354       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    371    371       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    468    468       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    479    479       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     54    100       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:20534510}.
FT   DISULFID    149    190       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:20534510}.
FT   DISULFID    235    291       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:20534510}.
FT   DISULFID    436    508       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   VAR_SEQ     311    336       VESGYVRLLGEVGTLQFAELHRSRTL -> RAATCGSWERW
FT                                AHYNLLSCIGAGHCR (in isoform 2).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_056008.
FT   VAR_SEQ     337   1106       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_056009.
FT   VARIANT      29     29       I -> F (in dbSNP:rs17110944).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_034377.
FT   VARIANT     180    180       S -> F (in dbSNP:rs17853027).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_035125.
FT   VARIANT     282    282       E -> K (in dbSNP:rs34586048).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042027.
FT   VARIANT     345    345       P -> S (in dbSNP:rs2229558).
FT                                /FTId=VAR_049717.
FT   VARIANT     485    485       E -> K (in dbSNP:rs41287110).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042028.
FT   VARIANT     561    561       R -> C (in IMF1; dbSNP:rs367543286).
FT                                {ECO:0000269|PubMed:23731537}.
FT                                /FTId=VAR_069925.
FT   VARIANT     584    584       P -> R (in KOGS; dbSNP:rs863224946).
FT                                {ECO:0000269|PubMed:25454926}.
FT                                /FTId=VAR_075865.
FT   VARIANT     589    589       Y -> H (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042029.
FT   VARIANT     658    658       L -> P (in IBGC4; no effect on protein
FT                                abundance; loss of PDGF beta receptor
FT                                activity; dbSNP:rs397509381).
FT                                {ECO:0000269|PubMed:23255827,
FT                                ECO:0000269|PubMed:24065723,
FT                                ECO:0000269|PubMed:26599395}.
FT                                /FTId=VAR_069320.
FT   VARIANT     660    660       P -> T (in IMF1; dbSNP:rs144050370).
FT                                {ECO:0000269|PubMed:23731542}.
FT                                /FTId=VAR_069926.
FT   VARIANT     665    665       V -> A (in PENTT; gain of function in
FT                                protein tyrosine kinase activity; shows
FT                                ligand-independent constitutive
FT                                signaling).
FT                                {ECO:0000269|PubMed:26279204}.
FT                                /FTId=VAR_075866.
FT   VARIANT     718    718       N -> Y (in dbSNP:rs35322465).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042030.
FT   VARIANT     882    882       T -> I (in a breast infiltrating ductal
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042031.
FT   VARIANT     987    987       R -> W (in IBGC4; decreased protein
FT                                abundance; no effect on receptor
FT                                activity; decreased PDGF signaling
FT                                pathway; dbSNP:rs397509382).
FT                                {ECO:0000269|PubMed:23255827,
FT                                ECO:0000269|PubMed:24065723,
FT                                ECO:0000269|PubMed:26599395}.
FT                                /FTId=VAR_069321.
FT   VARIANT    1071   1071       E -> V (in IBGC4; no effect on protein
FT                                abundance; no effect on receptor
FT                                activity; decreased PDGF signaling
FT                                pathway). {ECO:0000269|PubMed:24065723,
FT                                ECO:0000269|PubMed:26599395}.
FT                                /FTId=VAR_075395.
FT   MUTAGEN     579    579       Y->F: Loss of kinase activity; when
FT                                associated with F-581. Strongly reduces
FT                                interaction with SRC family kinases. No
FT                                effect on interaction with GRB10.
FT                                {ECO:0000269|PubMed:10454568,
FT                                ECO:0000269|PubMed:7685273}.
FT   MUTAGEN     581    581       Y->F: Loss of kinase activity; when
FT                                associated with F-579. No effect on
FT                                interaction with GRB10.
FT                                {ECO:0000269|PubMed:10454568,
FT                                ECO:0000269|PubMed:7685273}.
FT   MUTAGEN     634    634       K->A,R: Loss of kinase activity.
FT                                Abolishes interaction with RASA1. No
FT                                effect on phosphatidylinositol 3-kinase
FT                                activity. {ECO:0000269|PubMed:1314164,
FT                                ECO:0000269|PubMed:1846866,
FT                                ECO:0000269|PubMed:20494825}.
FT   MUTAGEN     716    716       Y->F: No effect neither on interaction
FT                                with GRB10 and RASA1 nor on
FT                                phosphatidylinositol 3-kinase activity.
FT                                {ECO:0000269|PubMed:10454568,
FT                                ECO:0000269|PubMed:1314164}.
FT   MUTAGEN     740    740       Y->F: Strongly reduces up-regulation of
FT                                cell proliferation; when associated with
FT                                F-751. Strongly decreases
FT                                phosphatidylinositol 3-kinase activity.
FT                                No effect on interaction with GRB10 and
FT                                RASA1. {ECO:0000269|PubMed:10454568,
FT                                ECO:0000269|PubMed:1314164,
FT                                ECO:0000269|PubMed:1375321,
FT                                ECO:0000269|PubMed:21679854}.
FT   MUTAGEN     751    751       Y->F: Strongly reduces up-regulation of
FT                                cell proliferation; when associated with
FT                                F-740. Abolishes phosphatidylinositol 3-
FT                                kinase activity and interaction with
FT                                NCK1, and slightly reduces interaction
FT                                with RASA1. No effect on interaction with
FT                                GRB10. {ECO:0000269|PubMed:10454568,
FT                                ECO:0000269|PubMed:1314164,
FT                                ECO:0000269|PubMed:1375321,
FT                                ECO:0000269|PubMed:1653029,
FT                                ECO:0000269|PubMed:21679854,
FT                                ECO:0000269|PubMed:7692233}.
FT   MUTAGEN     763    763       Y->F: No effect on interaction with RASA1
FT                                and on phosphatidylinositol 3-kinase
FT                                activity. {ECO:0000269|PubMed:1314164}.
FT   MUTAGEN     771    771       Y->F: Loss of interaction with GRB10.
FT                                Abolishes interaction with RASA1. No
FT                                effect on phosphatidylinositol 3-kinase
FT                                activity. {ECO:0000269|PubMed:10454568,
FT                                ECO:0000269|PubMed:1314164,
FT                                ECO:0000269|PubMed:1375321}.
FT   MUTAGEN     775    775       Y->F: No effect on interaction with RASA1
FT                                and on phosphatidylinositol 3-kinase
FT                                activity. {ECO:0000269|PubMed:1314164}.
FT   MUTAGEN     778    778       Y->F: Strongly reduces expression levels.
FT                                {ECO:0000269|PubMed:1314164}.
FT   MUTAGEN     857    857       Y->F: Reduces kinase activity. No effect
FT                                on interaction with GRB10. Abolishes
FT                                interaction with RASA1. No effect on
FT                                phosphatidylinositol 3-kinase activity.
FT                                {ECO:0000269|PubMed:10454568,
FT                                ECO:0000269|PubMed:1314164,
FT                                ECO:0000269|PubMed:1653029,
FT                                ECO:0000269|PubMed:20494825}.
FT   MUTAGEN    1009   1009       Y->F: No effect on interaction with
FT                                GRB10. Abolishes interaction with PLCG1;
FT                                when associated with F-1021.
FT                                {ECO:0000269|PubMed:10454568,
FT                                ECO:0000269|PubMed:1396585,
FT                                ECO:0000269|PubMed:7691811}.
FT   MUTAGEN    1021   1021       Y->F: Strongly reduces up-regulation of
FT                                cell proliferation. Abolishes interaction
FT                                with PLCG1; when associated with F-1009.
FT                                No effect on interaction with GRB10.
FT                                {ECO:0000269|PubMed:10454568,
FT                                ECO:0000269|PubMed:1396585,
FT                                ECO:0000269|PubMed:17620338,
FT                                ECO:0000269|PubMed:21679854}.
FT   CONFLICT    241    241       E -> D (in Ref. 2; AAA36427).
FT                                {ECO:0000305}.
FT   STRAND       40     43       {ECO:0000244|PDB:3MJG}.
FT   STRAND       50     58       {ECO:0000244|PDB:3MJG}.
FT   STRAND       61     64       {ECO:0000244|PDB:3MJG}.
FT   STRAND       70     75       {ECO:0000244|PDB:3MJG}.
FT   STRAND       81     87       {ECO:0000244|PDB:3MJG}.
FT   HELIX        92     94       {ECO:0000244|PDB:3MJG}.
FT   STRAND       96    101       {ECO:0000244|PDB:3MJG}.
FT   STRAND      114    119       {ECO:0000244|PDB:3MJG}.
FT   HELIX       132    135       {ECO:0000244|PDB:3MJG}.
FT   STRAND      136    141       {ECO:0000244|PDB:3MJG}.
FT   STRAND      145    147       {ECO:0000244|PDB:3MJG}.
FT   STRAND      158    164       {ECO:0000244|PDB:3MJG}.
FT   TURN        175    177       {ECO:0000244|PDB:3MJG}.
FT   STRAND      178    181       {ECO:0000244|PDB:3MJG}.
FT   STRAND      185    194       {ECO:0000244|PDB:3MJG}.
FT   STRAND      197    200       {ECO:0000244|PDB:3MJG}.
FT   STRAND      204    208       {ECO:0000244|PDB:3MJG}.
FT   STRAND      217    221       {ECO:0000244|PDB:3MJG}.
FT   STRAND      223    226       {ECO:0000244|PDB:3MJG}.
FT   STRAND      231    239       {ECO:0000244|PDB:3MJG}.
FT   STRAND      241    248       {ECO:0000244|PDB:3MJG}.
FT   STRAND      252    255       {ECO:0000244|PDB:3MJG}.
FT   STRAND      261    265       {ECO:0000244|PDB:3MJG}.
FT   TURN        267    270       {ECO:0000244|PDB:3MJG}.
FT   STRAND      271    280       {ECO:0000244|PDB:3MJG}.
FT   STRAND      287    295       {ECO:0000244|PDB:3MJG}.
FT   TURN        296    299       {ECO:0000244|PDB:3MJG}.
FT   STRAND      300    311       {ECO:0000244|PDB:3MJG}.
FT   HELIX       530    556       {ECO:0000244|PDB:2L6W}.
SQ   SEQUENCE   1106 AA;  123968 MW;  038C15E531D6E89D CRC64;
     MRLPGAMPAL ALKGELLLLS LLLLLEPQIS QGLVVTPPGP ELVLNVSSTF VLTCSGSAPV
     VWERMSQEPP QEMAKAQDGT FSSVLTLTNL TGLDTGEYFC THNDSRGLET DERKRLYIFV
     PDPTVGFLPN DAEELFIFLT EITEITIPCR VTDPQLVVTL HEKKGDVALP VPYDHQRGFS
     GIFEDRSYIC KTTIGDREVD SDAYYVYRLQ VSSINVSVNA VQTVVRQGEN ITLMCIVIGN
     EVVNFEWTYP RKESGRLVEP VTDFLLDMPY HIRSILHIPS AELEDSGTYT CNVTESVNDH
     QDEKAINITV VESGYVRLLG EVGTLQFAEL HRSRTLQVVF EAYPPPTVLW FKDNRTLGDS
     SAGEIALSTR NVSETRYVSE LTLVRVKVAE AGHYTMRAFH EDAEVQLSFQ LQINVPVRVL
     ELSESHPDSG EQTVRCRGRG MPQPNIIWSA CRDLKRCPRE LPPTLLGNSS EEESQLETNV
     TYWEEEQEFE VVSTLRLQHV DRPLSVRCTL RNAVGQDTQE VIVVPHSLPF KVVVISAILA
     LVVLTIISLI ILIMLWQKKP RYEIRWKVIE SVSSDGHEYI YVDPMQLPYD STWELPRDQL
     VLGRTLGSGA FGQVVEATAH GLSHSQATMK VAVKMLKSTA RSSEKQALMS ELKIMSHLGP
     HLNVVNLLGA CTKGGPIYII TEYCRYGDLV DYLHRNKHTF LQHHSDKRRP PSAELYSNAL
     PVGLPLPSHV SLTGESDGGY MDMSKDESVD YVPMLDMKGD VKYADIESSN YMAPYDNYVP
     SAPERTCRAT LINESPVLSY MDLVGFSYQV ANGMEFLASK NCVHRDLAAR NVLICEGKLV
     KICDFGLARD IMRDSNYISK GSTFLPLKWM APESIFNSLY TTLSDVWSFG ILLWEIFTLG
     GTPYPELPMN EQFYNAIKRG YRMAQPAHAS DEIYEIMQKC WEEKFEIRPP FSQLVLLLER
     LLGEGYKKKY QQVDEEFLRS DHPAILRSQA RLPGFHGLRS PLDTSSVLYT AVQPNEGDND
     YIIPLPDPKP EVADEGPLEG SPSLASSTLN EVNTSSTISC DSPLEPQDEP EPEPQLELQV
     EPEPELEQLP DSGCPAPRAE AEDSFL
//
